Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 18:3:188.
doi: 10.3389/fneur.2012.00188. eCollection 2012.

Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?

Kerrie L McDonald  1 , Grace Aw, Paul Kleihues
Affiliations

Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?

Kerrie L McDonald et al. Front Neurol. .

Abstract

Thousands of articles describing biomarkers predictive of treatment and prognostic of survival in cancer have been published, yet only a handful of biomarkers are currently used routinely in the clinic. Biomarkers need to be analytically standardized, validated, and clinically useful. This review will address the challenges and ways in which we can improve our discovery and translation of prospective biomarkers from the lab into validated diagnostic tests with a specific focus on patients diagnosed with glioblastoma and MGMT promoter methylation status. There has been long-held enthusiasm to use MGMT promoter methylation as a predictive biomarker for patients treated with the alkylating agent, temozolomide; however in the majority of centers around the world, this has not yet transpired.

Keywords: MGMT; biomarkers; glioblastoma; treatment response; tumor heterogeneity.

PubMed Disclaimer

References

    1. Agarwal M. L., Agarwal A., Taylor W. R., Stark G. R. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92, 8493–849710.1073/pnas.92.21.9440 - DOI - PMC - PubMed
    1. Ahluwalia M. S. (2011). 2010 Society for neuro-oncology annual meeting: a report of selected studies. Expert Rev. Anticancer Ther. 11, 161–16310.1586/era.11.166 - DOI - PubMed
    1. Bady P., Sciuscio D., Diserens A. C., Bloch J., Van Den Bent M. J., Marosi C., et al. (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 124, 547–56010.1007/s00401-012-1016-2 - DOI - PMC - PubMed
    1. Brell M., Tortosa A., Verger E., Gil J. M., Vinolas N., Villa S., et al. (2005). Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin. Cancer Res. 11, 5167–517410.1158/1078-0432.CCR-05-0230 - DOI - PubMed
    1. Brock C. S., Newlands E. S., Wedge S. R., Bower M., Evans H., Colquhoun I., et al. (1998). Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 58, 4363–4367 - PubMed